2-bromo-2-phenyl-1-(4-(trifluoromethyl)phenyl)ethan-1-one | 122023-36-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 2-bromo-2-phenyl-1-(4-(trifluoromethyl)phenyl)ethan-1-one
• 英文别名: α-bromo-α-phenyl-4-trifluoromethylacetophenone；2-bromo-2-phenyl-1-(4-trifluoromethylphenyl)ethanone；2-Bromo-2-phenyl-1-[4-(trifluoromethyl)phenyl]ethanone
• CAS: 122023-36-3
• 化学式: C₁₅H₁₀BrF₃O
• 分子量: 343.143
• InChiKey: SUTLWVFJKFZUTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-bromo-2-phenyl-1-(4-(trifluoromethyl)phenyl)ethan-1-one 在 肼 作用下， 以 乙腈 为溶剂， 反应 0.42h， 生成 4-phenyl-5-(4-(trifluoromethyl)phenyl)-1H-imidazol-2-amine
  参考文献：
  名称：

  Structure−Activity Relationship of 4(5)-Aryl-2-amino-1H-imidazoles, N1-Substituted 2-Aminoimidazoles and Imidazo[1,2-a]pyrimidinium Salts as Inhibitors of Biofilm Formation by Salmonella Typhimurium and Pseudomonas aeruginosa

  摘要：

  A library of 112 4(5)-aryl-2-amino-1H-imidazoles, 4,5-diphenyl-2-amino-1H-imidazoles, and N1-substituted 4(5)-phenyl-2-aminoimidazoles was synthesized and tested for the antagonistic effect against biofilm formation by Salmonella Typhimurium and Pseudomonas aeruginosa. The substitution pattern of the 4(5)phenyl group and the nature of the N1-substituent were found to have a major effect on the biofilm inhibitory activity. The most active compounds of this series were shown to inhibit the biofilm formation at low micromolar concentrations. Furthermore, the influence of 6 imidazo[1,2-a]pyrimidines and 18 imidazo[1,2-a]pyrimidinium salts on the biofilm formation was tested. These compounds are the chemical precursors of the 2-aminoimidazoles in our synthesis pathway. A good correlation was found between the activity of the imidazo[1,2-a]pyrimidinium salts and their corresponding 2-aminoimidazoles, supporting the hypothesis that the imidazo[1,2-a]pyrimidinium salts are possibly cleaved by cellular nucleophiles to form the active 2-aminoimidazoles. However, the imidazo[1,2-a]pyrimidines did not show any biofilm inhibitory activity, indicating that these molecules are not susceptible to in situ degradation to 2-aminoimidazoles. Finally, we demonstrated the lack of biofilm inhibitory activity of an array of 37 2N-substituted 2-aminopyrimidines, which are the chemical precursors of the imidazo[1,2-a]pyrimidinium salts in our synthesis pathway.

  DOI：

  10.1021/jm1011148
• 作为产物：
  描述：

  2-苯基-1-[4-(三氟甲基)苯基]-乙酮 在 溴 作用下， 以 氯仿 为溶剂， 反应 2.0h， 生成 2-bromo-2-phenyl-1-(4-(trifluoromethyl)phenyl)ethan-1-one
  参考文献：
  名称：

  可溶性环氧化物水解酶磷酸酶结构域的体内第一个活性抑制剂的发现。

  摘要：

  新兴的药理学目标可溶性环氧化物水解酶（sEH）是一种双功能酶，在两个不同的域中表现出两种不同的催化活性。尽管对C末端水解酶结构域的生理作用进行了充分研究，但关于其磷酸酶活性的信息却鲜为人知，它位于sEH（sEH-P）的N末端磷酸酶结构域中。本文中，我们报道了在体内可应用的人和大鼠sEH-P的第一种抑制剂的发现和优化。与抑制剂复合的sEH磷酸酶结构域的X射线结构分析提供了小分子sEH-P抑制的分子基础的见解，并有助于合理化结构-活性关系。4-（4-（3,4-二氯苯基）-5-苯基恶唑-2-基）丁酸（22b，

  DOI：

  10.1021/acs.jmedchem.9b00445

文献信息

• Ketone Synthesis from Benzyldiboronates and Esters: Leveraging α-Boryl Carbanions for Carbon–Carbon Bond Formation
  作者：Boran Lee、Paul J. Chirik

  DOI：10.1021/jacs.9b11944

  日期：2020.2.5

  method for the synthesis of ketones from readily available esters and benzyldiboronates is described. The synthetic method is compatible with a host of sterically differentiated alkyl groups, alkenes, acidic protons, amides and aryl rings having common organic functional groups. With esters bearing α-stereocenters, high enantiomeric excess was maintained during ketone formation, establishing minimal competing

  描述了从容易获得的酯和苄基二硼酸酯合成酮的醇盐促进方法。该合成方法与具有共同有机官能团的大量空间上不同的烷基、烯烃、酸质子、酰胺和芳环兼容。对于带有α-立体中心的酯，在酮形成过程中保持高对映体过量，通过去质子化建立最小的竞争外消旋化。在 23 ºC 下监测二硼酸苄酯和 LiOtBu 在四氢呋喃中的反应，可以鉴定由脱硼作用形成的 α-硼基碳负离子、去质子化和醇盐加成形成“-ate”复合物的产物。将 4-三氟甲基苯甲酸酯添加到该混合物中确定了 α-硼基碳负离子负责 CC 键的形成和最终的酮合成。阐明这种中间体的作用利用了额外的成键化学，并使具有 α-卤素原子和具有四个不同碳取代基的四元中心的酮的一锅法合成成为可能。
• 1,3-heterocyclic-substituted alkane
  申请人：Imperial Chemical Industries PLC

  公开号：US04957934A1

  公开（公告）日：1990-09-18

  A 2-propanol derivative of the formula I, wherein R.sup.1 and R.sup.5, which may be the same or different, are each a triazolyl, imidazolyl, pyridyl or pyrimidinyl radical; R.sup.2, R.sup.3 and R.sup.4, which may be the same or different, are each a hydrogen atom, a 1-6C alkyl, halogenoalkyl or alkoxy radical, a 3-8C cycloalkyl radical, or a phenyl, naphthyl, phenoxy, naphthyloxy or phenyl (1-6C alkyl) radical, in each of which the aryl group optionally bears one or more substituents selected from halogen atoms, amino, carboxamido, cyano and nitro radicals, 1-6C alkyl, halogenoalkyl, alkoxy, halogenoalkoxy and alkylamino radicals, 3-8C cycloalkyl radicals, di(1-6C alkyl)amino radicals and 2-6C alkoxycarbonyl radicals; R.sup.6 is a phenyl or naphthyl radical optionally bearing one or more substituents as defined above; X is a direct bond, an alkylene, alkenylene or alkynylene radical, or an oxyalkylene or thioalkylene radical wherein respectively the oxygen or sulphur atom is bonded to R.sup.6 or a phenylalkylene radical in which the phenyl group bears one or more substituents as defined above for R.sup.6 ; and Y is a hydrogen or halogen atom, a hydroxy, cyano or carbamoyl radical, or a phenyl(1-6C alkoxy) radical in which the phenyl group bears one or more substituents as defined above for R.sup.6 ; provided that, when Y is a cyano or carbamoyl radical, neither R.sup.2, R.sup.3 nor R.sup.4 may be an alkoxy or aryloxy radical, and either R.sup.2 is a hydrogen atom, or R.sup.3 and R.sup.4 are both hydrogen atoms; and provided that, when R.sup.1 and R.sup.5 are each a 1,2,4-triazol-1-yl radical, R.sup.2 is hydrogen and Y is a hydroxy radical, R.sup.3 and R.sup.4 may not be hydrogen or methyl when X is a direct bond, and R.sup.3 and R.sup.4 may not be hydrogen when X is a methylene radical; and for those compounds which contain a basic nitrogen atom, the pharmaceutically acceptable acid additon salts thereof.

  化学式I的2-丙醇衍生物，其中R.sup.1和R.sup.5，可以相同也可以不同，分别是三唑基、咪唑基、吡啶基或嘧啶基基团；R.sup.2、R.sup.3和R.sup.4，可以相同也可以不同，分别是氢原子、1-6碳烷基、卤代烷基或烷氧基基团、3-8碳环烷基基团，或苯基、萘基、苯氧基、萘氧基或苯（1-6碳烷基）基团，其中芳基基团可选地带有一个或多个卤素原子、氨基、羧酰胺基、氰基和硝基基团、1-6碳烷基、卤代烷基、烷氧基、卤代烷氧基和烷基氨基基团、3-8碳环烷基基团、二（1-6碳烷基）氨基基团和2-6碳氧羰基基团；R.sup.6是一个苯基或萘基基团，可选地带有如上所定义的一个或多个取代基；X是一个直链键、烷基、烯基或炔基基团，或氧烷基或硫烷基基团，其中氧或硫原子分别与R.sup.6或一个苯基烷基基团结合，该苯基带有如上所定义的一个或多个取代基；Y是氢原子或卤素原子、羟基、氰基或氨基甲酰基基团，或苯（1-6碳烷氧基）基团，其中苯基带有如上所定义的一个或多个取代基；但是，当Y是氰基或氨基甲酰基基团时，R.sup.2、R.sup.3或R.sup.4不能是烷氧基或芳基氧基基团，且要么R.sup.2是氢原子，要么R.sup.3和R.sup.4都是氢原子；此外，当R.sup.1和R.sup.5分别是1,2,4-三唑-1-基基团时，R.sup.2是氢，Y是羟基，当X是直链键时，R.sup.3和R.sup.4不能是氢或甲基，当X是亚甲基基团时，R.sup.3和R.sup.4不能是氢；对于含有碱性氮原子的化合物，其药学上可接受的酸盐。
• UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF
  申请人：Sugawara Yuji

  公开号：US20100234395A1

  公开（公告）日：2010-09-16

  Discloses is a pharmaceutical agent comprising an ureide derivative represented by the formula: or a pharmaceutically acceptable salt thereof as an active ingredient. The ureide derivative or the pharmaceutically acceptable salt thereof is useful for the relief of a pain or the treatment or prevention of neurogenic pain.

  Discloses是一种药物代理剂，包括一种由以下公式表示的尿素衍生物或其药学上可接受的盐作为活性成分。该尿素衍生物或其药学上可接受的盐对缓解疼痛或治疗或预防神经源性疼痛有用。
• Heterocyclic Compounds
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0299684A1

  公开（公告）日：1989-01-18

  A 2-propanol derivative of the formula I, wherein R' and R5, which may be the same or different, are each a triazolyl, imidazolyl, pyridyl or pyrimidinyl radical; R2, R3 and R4, which may be the same or different, are each a hydrogen atom, a 1-6C alkyl, halogenoalkyl or alkoxy radical, a 3-8C cycloalkyl radical, or a phenyl, naphthyl, phenoxy, naphthyloxy or phenyl(1-6C alkyl) radical, in each of which the aryl group optionally bears one or more substituents selected from halogen atoms, amino, carboxamido, cyano and nitro radicals, 1-6C alkyl, halogenoalkyl, alkoxy, halogenoalkoxy and alkylamino radicals, 3-8C cycloalkyl radicals, di(1-6C alkyl)amino radicals and 2-6C alkoxycarbonyl radicals; R6 is a phenyl or naphthyl radical optionally bearing one or more substituents as defined above; X is a direct bond, an alkylene, alkenylene or alkynylene radical, or an oxyalkylene or thioalkylene radical wherein respectively the oxygen or sulphur atom is bonded to R6 or a phenylalkenylene radical in which the phenyl group bears one or more substituents as defined above for R6; and Y is a hydrogen or halogen atom, a hydroxy, cyano or carbamoyl radical, or a phenyl(1-6C alkoxy) radical in which the phenyl group bears one or more substituents as defined above for R6; provided that, when Y is a cyano or carbamoyl radical, neither R2, R3 nor R4 may be an alkoxy or aryloxy radical, and either R2 is a hydrogen atom, or R3 and R4 are both hydrogen atoms; and provided that, when R' and R5 are each a 1,2,4-triazol-1-yl radical, R2 is , hydrogen and Y is a hydroxy radical, R3 arid R4 may not be hydrogen or methyl when X is a direct bond, and R3 and R4- may not be hydrogen when X is a methylene radical; and for those compounds which contain a basic nitrogen atom, the pharmaceutically acceptable acid addition salts thereof.

  式 I 的 2-丙醇衍生物，其中 R'和 R5（可以相同或不同）各自是三唑基、咪唑基、吡啶基或嘧啶基；R2、R3 和 R4（可以相同或不同）各自是氢原子、1-6C 烷基、卤代烷基或烷氧基、3-8C 环烷基或苯基、萘基、苯氧基、萘氧基或苯基（1-6C 烷基）基、其中每个芳基任选带有一个或多个选自卤素原子、氨基、羧基、氰基和硝基、1-6C 烷基、卤代烷基、烷氧基、卤代烷氧基和烷基氨基、3-8C 环烷基、二（1-6C 烷基）氨基和 2-6C 烷氧基羰基的取代基；R6 是苯基或萘基，可选择带有一个或多个如上定义的取代基；X 是直接键、亚烷基、亚烯基或亚炔基，或氧亚烷基或硫代亚烷基，其中氧原子或硫原子分别与 R6 或苯基亚烯基键合，其中苯基带有一个或多个如上文对 R6 所定义的取代基；以及 Y 是氢原子或卤素原子、羟基、氰基或氨基甲酰基，或苯基（1-6C 烷氧基）基，其中苯基带有一个或多个如上文对 R6 所定义的取代基；但当 Y 为氰基或氨基甲酰基时，R2、R3 或 R4 均不得为烷氧基或芳氧基基，且 R2 为氢原子，或 R3 和 R4 均为氢原子；当 R'和 R5 各为 1,2,4-三唑-1-基时，R2 为氢原子，Y 为羟基，当 X 为直接键时，R3 和 R4 不得为氢原子或甲基，当 X 为亚甲基时，R3 和 R4- 不得为氢原子。
• UREIDE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP2009006A1

  公开（公告）日：2008-12-31

  This invention relates to a pharmaceutical comprising, as an active ingredient, a ureide derivative represented by formula: or a pharmaceutically acceptable salt thereof. The ureide derivative or a pharmaceutically acceptable salt thereof according to the present invention is useful for relieving pain and treating or preventing neuropathic pain.

  本发明涉及一种药物，其活性成分包括由式表示的脲衍生物： 或其药学上可接受的盐。根据本发明的脲苷衍生物或其药学上可接受的盐可用于缓解疼痛、治疗或预防神经性疼痛。